ALLO(Allogene Therapeutics, Inc.) · 财务报表

ALLO(Allogene Therapeutics, Inc.) 的财务报表:医疗保健,生物技术。数据来自 SEC 公开申报与市场行情,不构成投资建议。

近年年度财务(SEC XBRL)
科目FY 截至 2021-12-31FY 截至 2022-12-31FY 截至 2023-12-31FY 截至 2024-12-31FY 截至 2025-12-31
营业收入$114.09M$156.00K$95.00K$22.00K$0
毛利润—————
营业利润−$180.19M−$335.54M−$327.74M−$273.20M−$209.31M
净利润−$182.05M−$340.41M−$327.26M−$257.59M−$190.89M
经营现金流−$184.81M−$220.52M−$237.73M−$200.30M−$149.25M
自由现金流−$206.26M−$225.71M−$239.25M−$200.99M−$149.63M
摊薄每股收益$-1.34$-2.38$-2.09$-1.32$-0.87

Allogene Therapeutics, Inc. ALLO